LHF-535 是一种抗病毒剂，对 Lassa，Machupo，Junin，VSVg 病毒的 EC50分别为<1 μM，<1 μM，<1 μM 和 1-10 μM，信息来自专利文献 WO2012006552A1 中的化合物 1。
产品描述
LHF-535 is an antiviral compound. It has EC50s of<1 μM,<1 μM,<1 μM, and 1-10 μM for Lassa, Machupo, Junin, and VSVg virus, respectively.
体外活性
LHF-535 is a small-molecule viral entry inhibitor that targets the arenavirus envelope glycoprotein (GP). LHF-535 inhibits Lassa GP-pseudotyped lentivirus (IC50: 0.1-0.3 nM). LHF-535 shows effective antiviral activity against a broad array of hemorrhagic fever arenaviruses [2].
体内活性
An increase in survival is also observed when the first dose of LHF-535 (10 mg/kg) is delayed by 1, 2, or 3 days after infection. LHF-535 (3, 10 or 30 mg/kg; orally; daily; 14 days) protects mice from a lethal challenge with Tacaribe virus and dramatically reduces viral titers in plasma, spleen, and liver [2].
Cas No.
1450929-77-7
分子式
C27H28N2O2
分子量
412.52
储存和溶解度
H2O:< 0.1 mg/mL (insoluble)
DMSO:96.67 mg/mL (234.34 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
